Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Biocryst Pharma Inc (NASDAQ: BCRX)

$6.33 USD -$0.16 (-2.47%)
Last Price $6.33
Net Change $-0.16 (-2.47%)
Bid $6.21
Ask Price $8.6
Open Price $6.45
Previous Close Price $6.49
High Price $6.56
Low Price $6.32
Number of Trades 3,676
Volume 695,344
Fifty Two Week High $9.25 (2017-03-21)
Fifty Two Week Low $2.49 (2016-05-05)
Average Daily Volume 1,551,852
Share Outstanding 80,380 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $-0.06 (2017-02-27)
2nd Quarter Earnings $-0.16 (2016-11-07)
3nd Quarter Earnings $-0.22 (2016-08-04)
4th Quarter Earnings $-0.31 (2016-05-05)
PE Ratio $0
EPS Growth $15.67
Recent Earnings $-0.06
Annual EPS $-0.75
Last Quarter EPS $
Market Capitalization $0.51B
Insider Shareholders % 0.058%
Annual Revenue $0B
No. Shares Outstanding 80,380
Inst. Shareholder % 72.83%
Annual Net Income $0B
TTM Net Profit Margin $100.54
1-Year Return 89.77%
3-Year Return -16.04%
5-Year Return 69.45%
5-Year Revenue Growth 34.16%
5-Year Earnings Growth -40.48%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD 15.67%
Dividends per Share $
Stock Split Ratio
Beta 3.45
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

BCRX News & Stock Updates